HGSI NVS: The monthly Albuferon data are ho-hum at best, IMO. In no way do these results suggest that Albuferon would garner more commercial success if dosed monthly rather than biweekly, which is the dosing schedule in the pending BLA/MAA. All told, I continue to think that Albuferon will be a commercial bust.
Market Data 
Markets 
AI
